<DOC>
	<DOCNO>NCT00870818</DOCNO>
	<brief_summary>The purpose study assess long term safety efficacy subject Type 1 Diabetes Mellitus complete Protege Study ( CP-MGA031-01 ) .</brief_summary>
	<brief_title>Protege Extension Trial - Long Term Follow Up Trial Subjects Who Completed Protege Study ( CP-MGA031-01 )</brief_title>
	<detailed_description>The primary objective extension study ass long-term safety , particular focus development serious adverse event ( SAEs ) , adverse event special interest ( AESIs ) include opportunistic infection lymphoproliferative disease , immediately reportable event ( IREs ) , subject recent-onset T1DM complete CP-MGA031-01 . The secondary objective extension study : 1 ) ass long-term efficacy ; 2 ) evaluate immunological effect ( North America ) ; 3 ) measure anti-teplizumab antibody level ; 4 ) ass Health Related Quality Life Questionnaires .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Complete Protocol CPMGA03101 ( i.e. , subject complete Study Day 728 , regardless many dos study drug receive ) . 2 . Provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Teplizumab</keyword>
	<keyword>Protege</keyword>
	<keyword>MGA031</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>T1DM</keyword>
	<keyword>MacroGenics</keyword>
</DOC>